Neumora Therapeutics(NMRA) - 2025 Q4 - Annual Results

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update New data for NMRA-511 supports unsurpassed clinical ef ect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study KEY PIPELINE HI ...